Inhibitor of gp130 (IC50
= 0.72 μ
M); blocks cytokine-triggered gp130 signaling. Induces gp130 phosphorylation and down regulates gp130 glycosylation; also abrogates STAT3 phosphorylation, nuclear translocation and inhibits the expression of downstream target genes. Delays tumor growth in a mouse xenograft model of human ovarian cancer. Orally active.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu et al.
Mol.Cancer Ther., 2013;12:937